Ceftazidime Pediatric Dose — Antimicrobial Reference
Ceftazidime is a third-generation cephalosporin with potent activity against gram-negative organisms, including Pseudomonas aeruginosa, through inhibition of bacterial cell wall synthesis. It is used in pediatric patients for serious gram-negative infections in select populations, including those with infectious disease, hematology-oncology, or cystic fibrosis indications. Due to its spectrum and resistance implications, use is restricted to subspecialty-approved clinical contexts.
Pediatric Dosing
Restricted to ID / HemOnc / CF-approved use only.
- Dose: 50 mg/kg IV every 8 hours
- Adult dose: 2 g IV every 8 hours
For a 20 kg child: 20 × 50 mg/kg = 1,000 mg (1 g) per dose IV every 8 hours. Consult institutional protocol for weight-based maximum dose caps and renal dose adjustments.
Indications and Clinical Context
Ceftazidime is indicated for serious gram-negative infections where Pseudomonas aeruginosa or other resistant gram-negative pathogens are suspected or confirmed. In pediatric practice, use is typically restricted to patients under the care of Infectious Disease (ID), Hematology-Oncology (HemOnc), or Cystic Fibrosis (CF) teams, reflecting its role in febrile neutropenia, pulmonary exacerbations in CF, and other high-risk infections where antipseudomonal coverage is required.
Restriction to subspecialty services aligns with antimicrobial stewardship principles, helping to preserve the drug’s efficacy and minimize emergence of resistance in vulnerable pediatric populations.
Administration and Monitoring
Ceftazidime is administered intravenously (IV). It is typically infused over 15–30 minutes; extended infusions may be used per institutional protocol. Ensure appropriate renal function assessment prior to initiation, as dose adjustments are required in renal impairment. Monitor for hypersensitivity reactions, particularly in patients with known cephalosporin or penicillin allergy.
- Route: IV (as specified)
- Frequency: every 8 hours
- Renal dosing: consult institutional protocol
- Monitor: renal function, CBC, signs of hypersensitivity, and superinfection
- Subspecialty approval required prior to initiation (ID / HemOnc / CF)
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.